

Tuane C R G Vieira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4107171/publications.pdf>

Version: 2024-02-01

22
papers

891
citations

566801

15
h-index

713013

21
g-index

22
all docs

22
docs citations

22
times ranked

1019
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Pressure Chemical Biology and Biotechnology. <i>Chemical Reviews</i> , 2014, 114, 7239-7267.	23.0	177
2	Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins. <i>Accounts of Chemical Research</i> , 2010, 43, 271-279.	7.6	104
3	The aggregation of mutant p53 produces prion-like properties in cancer. <i>Prion</i> , 2014, 8, 75-84.	0.9	90
4	Prion Protein Complexed to N2a Cellular RNAs through Its N-terminal Domain Forms Aggregates and Is Toxic to Murine Neuroblastoma Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 19616-19625.	1.6	78
5	Heparin binding confers prion stability and impairs its aggregation. <i>FASEB Journal</i> , 2014, 28, 2667-2676.	0.2	57
6	Heparin Binding by Murine Recombinant Prion Protein Leads to Transient Aggregation and Formation of RNA-Resistant Species. <i>Journal of the American Chemical Society</i> , 2011, 133, 334-344.	6.6	56
7	Liquid-liquid phase transitions and amyloid aggregation in proteins related to cancer and neurodegenerative diseases. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 118, 289-331.	1.0	50
8	Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands. <i>Chemical Science</i> , 2021, 12, 7334-7349.	3.7	48
9	The Status of p53 Oligomeric and Aggregation States in Cancer. <i>Biomolecules</i> , 2020, 10, 548.	1.8	40
10	Acharan sulfate, the new glycosaminoglycan from <i>Achatina fulica</i> Bowdich 1822. <i>FEBS Journal</i> , 2004, 271, 845-854.	0.2	32
11	PrP interactions with nucleic acids and glycosaminoglycans in function and disease. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 132.	3.0	30
12	The role of RNA in mammalian prion protein conversion. <i>Wiley Interdisciplinary Reviews RNA</i> , 2012, 3, 415-428.	3.2	26
13	Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion. <i>Methods</i> , 2011, 53, 306-317.	1.9	24
14	Modulation of p53 and prion protein aggregation by RNA. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 933-940.	1.1	17
15	Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 585896.	2.0	16
16	Prion protein-coated magnetic beads: Synthesis, characterization and development of a new ligands screening method. <i>Journal of Chromatography A</i> , 2015, 1379, 1-8.	1.8	12
17	Nucleic acid actions on abnormal protein aggregation, phase transitions and phase separation. <i>Current Opinion in Structural Biology</i> , 2022, 73, 102346.	2.6	12
18	Second-Generation RT-QuIC Assay for the Diagnosis of Creutzfeldt-Jakob Disease Patients in Brazil. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 929.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Viral and Prion Infections Associated with Central Nervous System Syndromes in Brazil. <i>Viruses</i> , 2021, 13, 1370.	1.5	8
20	In Vitro Prion Amplification Methodology for Inhibitor Screening. <i>Methods in Molecular Biology</i> , 2019, 1873, 305-316.	0.4	3
21	Rabbit PrP Is Partially Resistant to in vitro Aggregation Induced by Different Biological Cofactors. <i>Frontiers in Neuroscience</i> , 2021, 15, 689315.	1.4	3
22	The use of second generation RT-QuIC assay for the diagnosis of Creutzfeldt Jakob disease patients in Brazil. <i>Alzheimer's and Dementia</i> , 2020, 16, e042232.	0.4	0